Cholewa, Brian D <br/><br/>
Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.  [electronic resource] 

 -  Cancer letters  01 2017 
 - 179-187 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2016.10.025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Caspase 3--metabolism<br/>Cell Cycle Proteins--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cyclin-Dependent Kinase Inhibitor p21--metabolism<br/>Dose-Response Relationship, Drug<br/>G2 Phase Cell Cycle Checkpoints--drug effects<br/>Humans<br/>Ki-67 Antigen--metabolism<br/>Melanoma--drug therapy<br/>Mice, Nude<br/>Molecular Targeted Therapy<br/>Mutation<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins--antagonists & inhibitors<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Pteridines--pharmacology<br/>S Phase Cell Cycle Checkpoints--drug effects<br/>Signal Transduction--drug effects<br/>Skin Neoplasms--drug therapy<br/>Time Factors<br/>Tumor Burden--drug effects<br/>Tumor Suppressor Protein p53--metabolism<br/>Xenograft Model Antitumor Assays<br/>Polo-Like Kinase 1